Schall_Gary

Gary R. Schall

Download IconDownload Print IconPrint
Schall_Gary

Gary R. Schall

Partner

  • Co-Chair, Emerging Company and Venture Capital Practice
New York + 1 212 295 6836 Boston + 1 617 526 6507

Gary Schall helps entrepreneurs and emerging companies navigate the many legal issues they face, from formation to equity, safe and note financings through exit events. He also represents venture capital funds in their investments in startups and high-growth companies. His clients are technology-based and span a broad range of industries, including e-commerce, mobile technologies, hardware, software, wearables, biotechnology and diagnostics. In the 2023 edition of The Legal 500 United States, Mr. Schall was recognized as a “Leading Lawyer” for his M&A/Corporate and Commercial: Venture Capital and Emerging Companies practice. In 2024, he was nominated by clients and selected as a Thomson Reuters' “Stand-out Lawyer.”

For more than 22 years, Mr. Schall has represented both venture capital firms and emerging companies advising on a variety of corporate matters, including formation and corporate governance, contract negotiations, employment and equity compensation matters, securities laws compliance and protection of intellectual property. He also counsels his clients through complex transactions, such as convertible debt and preferred stock financings, joint ventures and buy- and sell-side mergers and acquisitions.

Mr. Schall particularly enjoys working with emerging companies—learn more about how he can support your startup on WilmerHaleLaunch.com.

Experience

Prior to joining WilmerHale, Mr. Schall was an of counsel for seven years at a law firm in Boston, Massachusetts. He also held associate positions while at other law firms in Boston and Princeton, New Jersey.

With a background in accounting, Mr. Schall relied on his knowledge of financial modeling to develop business solutions for his clients. He also drew from his background and experiences in order to advise a number of venture capital firms and emerging companies on an array of corporate transactions. 

Professional Activities

Mr. Schall is a member of the American Bar Association and serves as Secretary on the Board of Directors of the Swedish-American Chamber of Commerce New England.

Additionally, Mr. Schall writes on topics related to entrepreneurship and has been featured on The Accelerators blog by The Wall Street Journal, Xconomy and TechCrunch. He is a frequent guest lecturer for various entrepreneurship organizations including the MIT Enterprise Forum of Cambridge, Swedish-American Chamber of Commerce New England and the Harvard i-lab.

Experience

  • Representative Financing Transactions

    • the $40 million Series A financing of Omeat Inc. by several venture capital firms;
    • the $12 million growth capital financing of Datanomix led by MK Capital and Joint Effects;
    • the $25 million Series C financing of Owl Labs Inc. by HP Tech Ventures;
    • the $75 million Series D investment in Sound Agriculture by Northpond Ventures;
    • the $50 million Series A financing of GiveCampus led by Silversmith Capital Partners;
    • SDC Capital Partners, LLC in its investment in IQ Fiber;
    • the Series A Preferred Stock financing of Datanomix by several strategic investors and venture capital firms;
    • the Series A Preferred Stock financing of Esme Learning Solutions, Inc. by a venture capital firm with a technology focus;
    • the Series Seed Preferred Stock financing of Cloze, Inc. by a venture capital firm;
    • the Series Seed Preferred Stock financing of a private smart video camera company by a venture capital firm and angel investors;
    • the Series Seed Preferred Stock financing of a private data management solutions company by a venture capital firm and angel investors;
    • the Series Seed Preferred Stock financing of Grove Labs Inc. by a venture capital firm;
    • the Series A Preferred Stock financing of Vtesse, Inc. by several strategic investors and venture capital firms;
    • the Series A Preferred Stock financing of Immuta, Inc. by multiple venture capital firms and its Series B financing by a venture capital firm and investors;
    • Spark Capital III L.P. in the Series A Preferred Stock Financing of PrefTV, Inc.;
    • Spark Capital III, L.P. in the Series A Preferred Stock financing of Orchard App Inc. and various investments in other portfolio companies;
    • the Series A-1 Preferred Stock financing of Vgo Communications, Inc. by a venture capital firm;
    • the Series B, Series B Extension and Series D Preferred Stock financing of MineralTree, Inc. by a strategic investor and several venture capital funds;
    • the Series B Preferred Stock financing of Fiksu, Inc. by a strategic investor and several venture capital funds;
    • the Series B Preferred Stock financing of Spark Therapeutics by a strategic investor and several venture capital funds;
    • Spark Capital III, L.P. and Matrix Partners IX, L.P. in the Series B Preferred Stock financing of Oculus VR, Inc.;
    • a venture capital firm in a Series B Preferred Stock financing of a private medical device company;
    • the Series C Preferred Stock financing of 1366 Technologies, Inc. by several strategic investors and venture capital firms;
    • the Series D Preferred Stock financing of MC10, Inc. by several strategic investors and venture capital firms; and
    • the Series D Preferred Stock financing of Cool Planet Energy Systems, Inc. by several strategic investors and venture capital firms.

  • Representative M&A Transactions and Joint Ventures

    • the acquisition of Community Funded Enterprises by GiveCampus, Inc;
    • the acquisition of NeuTrace, Inc. by Anumana, Inc.;
    • the acquisition of Forendo Pharma by Organon;
    • the acquisition of Regal Software by MineralTree, Inc.;
    • the acquisition of Exonics Therapeutics, Inc. by Vertex Pharmaceuticals, Inc.;
    • the acquisition of Smarterer Inc. by Pluralsight Inc.;
    • the acquisition of an angel-backed patient reported outcomes solutions provider by a private equity-backed patient experience solutions provider;
    • the acquisition of a venture-backed medical device company by a public medical device company;
    • the joint venture of a venture-backed company and a public grocery company; and
    • the joint venture of Atlas Venture Fund and a public pharmaceutical company.

Recognition

  • Named a Thomson Reuters Stand-out Lawyer – independently rated and selected by clients
  • Recognized by The Legal 500 United States for his Venture Capital and Emerging Companies Practice

Insights & News

View all of Gary's insights & news

Credentials

  • Education

    • JD, Vanderbilt University Law School, 2000

      Articles Editor, Vanderbilt Journal of Transnational Law, Order of the Coif

    • MBA, St. John’s University, 1991

    • BS, Finance, Lehigh University, 1987

  • Admissions

    • New York

    • Massachusetts

Credentials

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel